{
  "id": "641c5201690f196b51000040",
  "type": "list",
  "question": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (NfL).",
  "ideal_answer": "Neurofilament light chain (NfL) is a biomarker of neurodegeneration and is associated with many diseases such as MS, CKD, Ataxia telangiectasia, Langerhans cell histiocytosis (LCH) and acute and chronic inflammatory polyneuropathies",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35575811",
    "http://www.ncbi.nlm.nih.gov/pubmed/34311152",
    "http://www.ncbi.nlm.nih.gov/pubmed/35075461",
    "http://www.ncbi.nlm.nih.gov/pubmed/35959400",
    "http://www.ncbi.nlm.nih.gov/pubmed/34313819",
    "http://www.ncbi.nlm.nih.gov/pubmed/36376097",
    "http://www.ncbi.nlm.nih.gov/pubmed/33759425",
    "http://www.ncbi.nlm.nih.gov/pubmed/34274959",
    "http://www.ncbi.nlm.nih.gov/pubmed/34283286",
    "http://www.ncbi.nlm.nih.gov/pubmed/36280258",
    "http://www.ncbi.nlm.nih.gov/pubmed/35750882",
    "http://www.ncbi.nlm.nih.gov/pubmed/33636389",
    "http://www.ncbi.nlm.nih.gov/pubmed/29630554",
    "http://www.ncbi.nlm.nih.gov/pubmed/35638376",
    "http://www.ncbi.nlm.nih.gov/pubmed/33108404",
    "http://www.ncbi.nlm.nih.gov/pubmed/33893614",
    "http://www.ncbi.nlm.nih.gov/pubmed/35582775",
    "http://www.ncbi.nlm.nih.gov/pubmed/35658739",
    "http://www.ncbi.nlm.nih.gov/pubmed/30055655",
    "http://www.ncbi.nlm.nih.gov/pubmed/34212756"
  ],
  "snippets": [
    {
      "text": "To evaluate the predictive value of serum neurofilament light chain (sNfL) and CSF NfL (cNfL) in patients with radiologically isolated syndrome (RIS) for evidence of disease activity (EDA) and clinical conversion (CC)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36280258",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36280258",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "eurodegeneration and astrocytic activation are pathologic hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36376097",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36376097",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "sNfL reflected acute disease activity in patients with MS at high risk of underlying progressive pathology",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36376097",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thus, sGFAP and sNfL levels may be used to stratify patients with progressive MS for clinical research studies and clinical trials and may inform clinical care.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36376097",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Associations between neurofilament light-chain protein, brain structure, and chronic kidney disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34274959",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Neurofilament light-chain (NfL) protein is a blood-based marker of neuroaxonal injury. We sought to (1) compare plasma NfL levels in children with chronic kidney disease (CKD) and healthy peers, (2) characterize the relationship between NfL level and kidney function, and (3) evaluate NfL as a predictor of abnormal brain structure in CKD",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34274959",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Within the CKD sample, NfL level is associated with abnormal kidney function and brain structure. Decreased kidney function may be linked to abnormal neuronal integrity in pediatric CKD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34274959",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Using single-molecule array assays, we evaluated longitudinal changes of serum neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and GFAP/NfL levels.R",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34212756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34283286",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "erum NfL and GFAP could be potential diagnostic biomarkers for BM in patients with lung cancer. We established a model that can provide individual diagnoses of BM. Higher NfL level may be associated with poor prognosis of patients with BM.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34283286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The 'Frontotemporal dementia-Amyotrophic lateral sclerosis Spectrum' (FAS) encompasses different phenotypes, including cognitive disorders (frontotemporal dementia, FTD) and/or motor impairments (amyotrophic lateral sclerosis, ALS). The aim of this study was to apprehend the specific uses of neurofilaments light chain (NfL) and phosphorylated neurofilaments heavy chain (pNfH) in a context of FAS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34313819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34313819",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33893614",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "NfL is a new potential progression biomarker in blood for neurodegeneration in A-T which increases with age.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33893614",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The neurofilament light chain (NfL) has emerged as a versatile biomarker for CNS-diseases and is approaching clinical use.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33759425",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ": Serum neurofilament light (sNfL) chain is a promising biomarker reflecting neuro-axonal injury in multiple sclerosis (MS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658739",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658739",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Serum NfL concentration was the only factor associated with disease worsening, indicating that sNfL is a useful biomarker in MS that might be relevant in a clinical setting.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658739",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients with Langerhans cell histiocytosis (LCH) may develop progressive neurodegeneration in the central nervous system (ND-CNS-LCH). Neurofilament light protein (NFL) in cerebrospinal fluid (CSF) is a promising biomarker to detect and monitor ND-CNS-LCH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35582775",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35582775",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Thus, our results suggest that p-NFL may be used to screen for ND-CNS-LCH. Further studies are encouraged, including the role of p-NFL for monitoring of ND-CNS-LCH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35582775",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35575811",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Circulating Neurofilament light chain (NfL) levels have been recognized as a sensitive prognostic and monitoring biomarker of neuroaxonal damage in various CNS disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35575811",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35638376",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "To investigate the diagnostic and prognostic value of axonal injury biomarkers in patients with inflammatory polyneuropathies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35638376",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer's disease (AD).METHODS: With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99\u00a0subjects with AD at the stage of mild cognitive impairment (MCI-AD; n\u2009=\u200925) or at the stage of early dementia (ADD; n\u2009=\u200933), and in nondemented controls (n\u2009=\u200941); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid \u03b2 (A\u03b2)1-42, A\u03b242/40, Tau, and pTau181), interpreted according to the Erla",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30055655",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The levels of neurofilament light chain (NfL) in both cerebrospinal fluid (CSF) and plasma have been related to degeneration in several neurodegenerative conditions including frontotemporal dementia (FTD) and NfL is currently considered as the most promising diagnostic and prognostic fluid biomarker in FTD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33108404",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30055655",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Neurofilament light chain (NfL) is a marker of brain atrophy and predictor of disease progression in rare diseases such as Huntington Disease, but also in more common neurological disorders such as Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33636389",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In conclusion, NfL plasma levels are elevated during ECM confirming brain damage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35750882",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Neurofilament light chain plasma levels are associated with area of brain damage in experimental cerebral malaria.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35750882",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Background: Neurofilament light chain (NfL) is an axonal cytoskeletal protein that is released into the extracellular space following neuronal or axonal injury associated with neurological conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and oth",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35959400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Increased levels of circulating neurofilament light chain (NfL), a biomarker of neuro-axonal injury, have been observed in patients with severe COVID-19.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35075461",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our results shown that plasma NfL levels increased with an increase in cognitive impairment across the three groups of PD patients: PD with normal cognition (PD-NC), 17.9\u00a0\u00b1\u00a08.9\u00a0pg/ml; PD with mild cognitive impairment (PD-MCI),21.9\u00a0\u00b1\u00a010.3\u00a0pg/ml; and PD dementia (PDD), 35.7\u00a0\u00b1\u00a021.7\u00a0pg/ml.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34311152",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In Alzheimer's disease (AD), neurofilament light chain (NFL), a neurofilament subunit, is elevated in the cerebrospinal fluid and blood",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29630554",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "the CKD sample, NfL level is associated with abnormal kidney function and brain structure. Decrea",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34274959",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "neuroaxonal damage in various CNS disordersNS disorders, neurodegenerative diseases, CNS disease, radiologically isolated syndrome (RIS), Chronic Kidney Disease, Brain Metastasis, cancer, The 'Frontotemporal dementia-Amyotrophic lateral sclerosis Spectrum' (FAS), Ataxia telangiectasia (A-T), Langerhans cell histiocytosis (LCH), Multiple Sclerosis, acute and chronic inflammatory polyneuropathies, ALS, Amyotrophic Lateral Sclerosis, Creutzfeldt Jacob syndrome, progressive supranuclear palsy, Alzheimer's Disease, Parkinson's disease, Myotonic dystrophy, frontotemporal dementia"
}